|
|
|
|
Lecanemab reduced markers of amyloid in early Alzheimers disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events. Longer trials are warranted to determine the efficacy and safety of lecanemab in early Alzheimers disease. |
|